GLP-1 medications like Semaglutide and Tirzepatide are clinically proven to help patients achieve significant, sustainable weight loss
Moving straight to 18:6 or OMAD in the first weeks of GLP-1 therapy is a common mistake
Starting with both peptides together makes it difficult to assess individual responses, but the strong safety profiles of both compounds make this a minor concern
the pH of a solution prepared from the water-soluble composition or a peptide salt of the present invention should be such that said pH will not exert any adverse influence upon the activity of the pharmacologically active peptide, but is within an acceptable range for injections in general and further, such that said pH will neither cause a great change in viscosity of the solution nor allow formation of a precipitate or the like
Small lapses by untrained or rushed team members leaving vials open, mishandling packaging, or returning samples to the wrong temperature can accumulate into significant problems over time
Patients addressing insulin resistance or obesity-related metabolic concerns under medical care